109 active
/
365 total (since 2015)
26
Phase 1 Active
74 total
52
Phase 2 Active
172 total
28
Phase 3 Active
82 total
19
Phase 4 Active
84 total
Top Sponsors (Industry)
Sorted by active Active Done Failed
Roche 6 10 0
EyeBiotech Ltd. 3 1 0
Novartis 2 10 3
Regeneron 2 4 0
EyePoint Pharmaceuticals, Inc. 2 3 0
Oculis 2 1 0
Frontera Therapeutics 2 0 0
Bayer 1 6 1
Kodiak Sciences Inc 1 0 4
Boehringer Ingelheim 1 3 0
Kyowa Kirin Co., Ltd. 1 0 1
AbbVie 1 1 0
Ashvattha Therapeutics, Inc. 1 1 0
Outlook Therapeutics, Inc. 1 1 0
Alimera Sciences 1 1 0
NCT07449936 NOT YET RECRUITING
COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
EyePoint Pharmaceuticals, Inc. n=240
NCT07449923 RECRUITING
CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
EyePoint Pharmaceuticals, Inc. n=240
NCT04503551 ACTIVE NOT RECRUITING
A Multicenter, Randomized Study in Participants With Diabetic Retinopathy Without Center-involved Diabetic Macular Edema To Evaluate the Efficacy, Safety, and Pharmacokinetics of Ranibizumab Delivered Via the Port Delivery System Relative to the Comparator Arm
Hoffmann-La Roche n=174
NCT04108156 RECRUITING
A Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Substudy to Evaluate the Safety of Re-implanting the PDS With Ranibizumab in Participants With DME
Hoffmann-La Roche n=634
NCT06790784 RECRUITING
Faricimab + PRP vs. Vitrectomy + Endolaser for Treatment of PDR
Jaeb Center for Health Research n=426
NCT01320345 ACTIVE NOT RECRUITING
The Fenofibrate And Microvascular Events in Type 1 Diabetes Eye.
University of Sydney n=412
NCT05066997 ACTIVE NOT RECRUITING
A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 1)
Oculis n=552
NCT06172257 ACTIVE NOT RECRUITING
A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 2)
Oculis n=401
NCT06957080 ACTIVE NOT RECRUITING
A Study of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME
EyeBiotech Ltd. n=1,054
NCT06422507 ACTIVE NOT RECRUITING
A Study to Learn More About How Well 8 Milligram Aflibercept Works and How Safe it is in Chinese Participants With Diabetic Macular Edema
Bayer n=333
NCT07235085 RECRUITING
A Study to Evaluate the Efficacy and Safety of OTX-TKI (Axitinib Implant) in Participants With Non-Proliferative Diabetic Retinopathy
Ocular Therapeutix, Inc. n=930
NCT04661358 RECRUITING
Fenofibrate for Prevention of DR Worsening
Jaeb Center for Health Research n=560
NCT06491914 ACTIVE NOT RECRUITING
A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)
Regeneron Pharmaceuticals n=1,118
NCT06817265 RECRUITING
Clinical Study on the Efficacy and Safety of TNTL in the Treatment of Non-proliferative Diabetic Retinopathy
Beletalent (Zhuhai) Pharmaceutical Co., Ltd n=360
NCT06571045 ACTIVE NOT RECRUITING
A Study to Evaluate the Efficacy and Safety of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME
EyeBiotech Ltd. n=984
NCT06305416 RECRUITING
A Efficacy and Safety Study of Ranibizumab 10mg/ml Injection (Incepta) in Patients With Diabetic Macular Edema
Incepta Pharmaceuticals Ltd n=70
NCT06951087 ENROLLING BY INVITATION
Intravitreal and Intracameral DEX in NPDR
Affiliated Hospital of Nantong University n=80
NCT06270836 ACTIVE NOT RECRUITING
A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer Compared With Sham Treatment in Participants With Diabetic Retinopathy (DR)
Kodiak Sciences Inc n=255
NCT05217680 RECRUITING
Clinical Study to Evaluate PRO-169 for Diabetic Macular Edema
Laboratorios Sophia S.A de C.V. n=442
NCT06201611 RECRUITING
Evaluating a Nitric Oxide Generator, Nebivolol as a Disease Modifier in Patients With Diabetic Neuropathy.
St. John's Research Institute n=120
NCT06606093 NOT YET RECRUITING
Evaluate the Efficacy and Safety of DWP16001 in Type 2 Diabetic Nephropathy with Moderate Renal Impairment Patients
Daewoong Pharmaceutical Co. LTD. n=348
NCT06595355 RECRUITING
Efficacy and Safety of Intravitreal Injection of Bevacizumab with and Without Oral Curcumin
Isfahan University of Medical Sciences n=52
NCT06572553 RECRUITING
Evaluation of Therapeutic Efficacy of Faricimab for Clinical AMD, DME, and RVO Patients
Second Affiliated Hospital, School of Medicine, Zhejiang University n=30
NCT06441591 RECRUITING
Clinical Outcome of Vinpocetine in Diabetic Nephropathy
Ain Shams University n=64
NCT06383702 NOT YET RECRUITING
A Study to Evaluate Pregabalin in Painful Diabetic Peripheral Neuropathy
CSPC Ouyi Pharmaceutical Co., Ltd. n=358
NCT05112861 ACTIVE NOT RECRUITING
A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual Impairment Due to Retinal Disorders
Outlook Therapeutics, Inc. n=120
NCT06068439 NOT YET RECRUITING
Study of the Protective Effect of Low-dose Aspirin on Renal Function in Patients With Early Diabetic Nephropathy
Second Affiliated Hospital, School of Medicine, Zhejiang University n=355
NCT05885503 RECRUITING
Efficacy and Safety of RC28-E Versus Aflibercept in Diabetic Macular Edema
RemeGen Co., Ltd. n=316
NCT04432831 COMPLETED
A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Diabetic Macular Edema
Hoffmann-La Roche n=1,479
NCT03436693 COMPLETED
Efficacy and Safety of Canagliflozin (TA-7284) in Patients With Diabetic Nephropathy
Tanabe Pharma Corporation n=308
NCT04278417 COMPLETED
Study of Efficacy and Safety of Brolucizumab Versus Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic Retinopathy
Novartis Pharmaceuticals n=689
NCT02427464 COMPLETED
Phase 3 Gene Therapy for Painful Diabetic Neuropathy
Helixmith Co., Ltd. n=507
NCT04055090 COMPLETED
Extension of Phase 3 Gene Therapy for Painful Diabetic Neuropathy
Helixmith Co., Ltd. n=101
NCT04469270 COMPLETED
Study to Assess Safety and Efficacy of Engensis in Painful Diabetic Peripheral Neuropathy
Helixmith Co., Ltd. n=162
NCT04429503 COMPLETED
Study of a High-Dose Aflibercept in Participants With Diabetic Eye Disease
Regeneron Pharmaceuticals n=660
NCT03622580 COMPLETED
A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema (YOSEMITE)
Hoffmann-La Roche n=940
NCT03622593 COMPLETED
A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema
Hoffmann-La Roche n=951
NCT05989126 COMPLETED
Study to Evaluate an 8 mg Aflibercept (EYLEA®) Prefilled Syringe (PFS)
Regeneron Pharmaceuticals n=35
NCT04516278 COMPLETED
A 3-month Study to Assess the Safety of ONS-5010 in Subjects With Visual Impairment Due to Retinal Disorders
Outlook Therapeutics, Inc. n=195
NCT03481660 COMPLETED
A Study of the Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema
Novartis Pharmaceuticals n=360
NCT04058067 COMPLETED
To Compare Brolucizumab to Aflibercept in Chinese Patients With Visual Impairment Due to Diabetic Macular Edema
Novartis Pharmaceuticals n=266
NCT05066230 TERMINATED
A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Non-proliferative Diabetic Retinopathy (NPDR)
Kodiak Sciences Inc n=253
NCT04603937 TERMINATED
A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)
Kodiak Sciences Inc n=459
NCT04611152 TERMINATED
A Trial to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)
Kodiak Sciences Inc n=460
NCT05487755 COMPLETED
Investigational and Comparative Study in the Management of Diabetic Nephropathy
Tanta University n=90
NCT03321513 COMPLETED
DRCR.Net Aflibercept vs. Bevacizumab + Deferred Aflibercept for the Treatment of CI-DME
Jaeb Center for Health Research n=270
NCT04741074 TERMINATED
Effect of Subcutaneous Semaglutide on Kidney Transplant Candidacy
Geisinger Clinic n=15
NCT03164785 COMPLETED
Efficacy and Safety of Jinshuibao Capsule on Diabetic Kidney Disease
Second Xiangya Hospital of Central South University n=202
NCT04739306 COMPLETED
Study to Compare Efficacy and Safety of CT-P42 in Comparison With Eylea in Patients With Diabetic Macular Edema
Celltrion n=348
NCT06115460 COMPLETED
The Impact of Sitagliptin as an Add on Therapy With Closed Loop Control in Adolescents With Diabetic Nephropathy
Ain Shams University n=46
NCT05569148 COMPLETED
A Study in Patients With Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema to Evaluate the Safety of the Faricimab Prefilled Syringe
Hoffmann-La Roche n=35
NCT03784443 WITHDRAWN
Combined Ranibizumab and Iluvien for Diabetic Macular Oedema
Imperial College London
NCT03550443 TERMINATED
A Phase 3 Study of Bardoxolone Methyl in Patients With Diabetic Kidney Disease; AYAME Study
Kyowa Kirin Co., Ltd. n=1,323
NCT02634333 COMPLETED
Anti-VEGF Treatment for Prevention of PDR/DME
Jaeb Center for Health Research n=399
NCT02689778 COMPLETED
Effect of Pirfenidone on Glomerular Filtration Rate and Albuminuria in Patients With Diabetic Nephropathy
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran n=62
NCT03610646 COMPLETED
Comparative Study to Evaluate the Efficacy and Safety of MYL-1701P and Eylea® in Subjects With Diabetic Macular Edema (DME)
Mylan Pharmaceuticals Inc n=355
NCT03481634 COMPLETED
Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema
Novartis Pharmaceuticals n=566
NCT04674800 COMPLETED
Extension Study of MYL-1701P-3001 for Safety and Efficacy
Mylan Pharmaceuticals Inc n=52
NCT03917472 COMPLETED
Efficacy and Safety of Brolucizumab vs Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema
Novartis Pharmaceuticals n=517
NCT02985619 COMPLETED
Bevacizumabe or Triamcinolone for Persistent Diabetic Macular Edema
University of Sao Paulo n=100
NCT05127525 TERMINATED
EffiCacy, Safety and ToLErability of a Novel Ocular ANtiseptic for Ocular Use (CLEAN)
iRenix Medical, Inc. n=5
NCT02545049 COMPLETED
Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease
Bayer n=7,352
NCT03702374 COMPLETED
Combined Antioxidant Therapy on Oxidative Stress, Mitochondrial Dysfunction Markers in Diabetic Retinopathy
University of Guadalajara n=132
NCT05271539 COMPLETED
Intravitreal Ranibizumab Versus Its Combination With Dexamethasone in The Treatment of Diabetic Macular Edema
Cairo University n=42
NCT03660345 COMPLETED
PPV With Internal Limiting Membrane Peeling for Treatment-Naïve DME
Rush Eye Associates n=11
NCT04253860 TERMINATED
Effect of Transcutaneous Electrical Nerve Stimulation in Diabetic Neuropathy
Centro Universitario de Tonalá n=20
NCT03478306 COMPLETED
Diabetic Retinopathy: Effects of Melatonin Treatment on Visual Functions and Circadian Rhythm
Glostrup University Hospital, Copenhagen n=31
NCT02858076 COMPLETED
Anti-VEGF vs. Prompt Vitrectomy for VH From PDR
Jaeb Center for Health Research n=205
NCT03105219 WITHDRAWN
IvaBradinE to Treat MicroalbumiNuria in Patients With Type 2 Diabetes and Coronary Heart Disease
Nanjing First Hospital, Nanjing Medical University
NCT03345901 TERMINATED
PROMINENT-Eye Ancillary Study (Protocol AD)
Jaeb Center for Health Research n=18
NCT02229175 WITHDRAWN
Laser vs Bevacizumab Injection Alone in Treatment of Diabetic Macular Edema
University of California, San Francisco
NCT02718326 COMPLETED
Study of the Efficacy and Safety of Intravitreal (IVT) Aflibercept for the Improvement of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy (NPDR)
Regeneron Pharmaceuticals n=402
NCT04288232 COMPLETED
Efficacy and Safety of Aflibercept as Mono-therapy in Treat and Extend Regimen for DME Patients in Taiwan
Taipei Veterans General Hospital, Taiwan n=45
NCT03173963 WITHDRAWN
Empaglifozin in Early Diabetic Kidney Disease
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NCT03143192 COMPLETED
Treatment of Diabetic Macular Edema With Aflibercept and Micropulse Laser
Keyvan Koushan n=31
NCT03113448 COMPLETED
0.075% Capsaicin Lotion for the Treatment of Painful Diabetic Neuropathy
Thammasat University n=42
Data: ClinicalTrials.gov